Abstract
Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema. The combination of the two drugs was associated with more adverse events without an increase in benefit. (ClinicalTrials.gov number, NCT00153101 [ClinicalTrials.gov].).
Keywords
RamiprilTelmisartanMedicineDiabetes mellitusACE inhibitorAngiotensin Receptor BlockersInternal medicineHeart failureCardiologyAngiotensin-converting enzymeVascular diseasePharmacologyEndocrinologyBlood pressure
Affiliated Institutions
Related Publications
Local Potentiation of Bradykinin-Induced Vasodilation by Converting-Enzyme Inhibition in Isolated Coronary Arteries
The interaction of angiotensin-converting enzyme (ACE) inhibitors and bradykinin was investigated in isolated bovine and human coronary arteries. Rings with and without endothel...
Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2
Background— Angiotensin-converting enzyme 2 (ACE2) has emerged as a novel regulator of cardiac function and arterial pressure by converting angiotensin II (Ang II) into the vaso...
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a med...
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or ...
Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction
Background —The Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study addressed prognostic factors and the effects of concomitant treatment and gly...
Publication Info
- Year
- 2008
- Type
- article
- Volume
- 358
- Issue
- 15
- Pages
- 1547-1559
- Citations
- 3470
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
3470
OpenAlex
Cite This
The ONTARGET Investigators
(2008).
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events.
New England Journal of Medicine
, 358
(15)
, 1547-1559.
https://doi.org/10.1056/nejmoa0801317
Identifiers
- DOI
- 10.1056/nejmoa0801317